Ifosfamide, Carboplatin, and Etoposide (ICE) in Combination with Regional Hyperthermia as Salvage Therapy in Patients with Locally Advanced Nonmetastatic and Metastatic Soft-Tissue Sarcoma
Table 4
Progression-free survival rates 3 and 6 months after initiation of ICE + RHT.
Patient subpopulation
PFR after 3 months (95% CI)
PFR after 6 months (95% CI)
Patients with nonmetastatic disease (n = 54, LA-STS)
82% (72–93%)
67% (56–82%)
Patients with metastatic disease (n = 56, M-STS)
54% (42–68%)
23% (14–37%)
Patients with metastatic disease without surgical treatment (n = 41)
